Immuneering Corporation Class A Common Stock
Veridion Score
Composite trend over time
Why is IMRX moving today?
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IMRX.
IMRX insider activity
Immuneering Corporation Class A Common Stock
2 insiders bought in the last 90 days
Net buying: $497K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-23 | Zeskind Benjamin J. | Insider | buy | $4.56 | 2,400 | 2,315,252 | $11K | SEC Form 4 |
| 2026-06-16 | 2026-06-15 | Hall Brett Matthew | Insider | buy | $4.15 | 6,035 | 382,531 | $25K | SEC Form 4 |
| 2026-03-17 | 2026-03-13 | Neufeld Leah R | Insider | buy | $4.29 | 3,628 | 29,598 | $16K | SEC Form 4 |
| 2026-01-21 | 2026-01-16 | Brakewood Harold Eugene | Insider | buy | $4.76 | 5,250 | 11,050 | $25K | SEC Form 4 |
| 2026-01-20 | 2026-01-15 | Schall Thomas J. | Insider | buy | $4.67 | 21,645 | 74,530 | $101K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 12 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moIMRX contract awards, year to date.
Public federal awards linked to this ticker.
IMRX lobbying filings, year to date.
Registered lobbying filings matched to Immuneering Corporation Class A Common Stock.